ESTRO 2024 - Abstract Book

S1724

Clinical - Lung

ESTRO 2024

2. Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D. Single fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans tasman radiation oncology group 13.01 phase 2 randomized clinical trial. JAMA oncology. 2021 Oct 1;7(10):1476-85.

2195

Digital Poster

Real world measurement of lung radiotherapy quality indicators- better data for better care delivery

Kim-Lin Chiew 1,2 , Shanley Chong 3 , Puma Sundaresan 4,5 , Margot Lehman 1,6 , Shalini K Vinod 7,2

1 Princess Alexandra Hospital, Radiation Oncology, Brisbane, Australia. 2 University of NSW, South Western Sydney Clinical School, Sydney, Australia. 3 Western Sydney Local Health District, Epidemiology, Sydney, Australia. 4 Western Sydney Local Health District, Radiation Oncology Network, Sydney, Australia. 5 The University of Sydney, Sydney Medical School, Sydney, Australia. 6 University of Queensland, School of Medicine, Brisbane, Australia. 7 Liverpool Hospital, Cancer Therapy Centre, Sydney, Australia

Purpose/Objective:

Quality indicators (QIs) aim to measure actual care received by patients compared to current evidence-based practice. Previous literature review has shown over 300 published quality indicators (QIs) for the management of lung cancer, with a disproportionate disparity in radiotherapy (RT) specific QIs compared to surgery or chemotherapy 1 . In this retrospective population-based study we investigate the feasibility of measuring RT QIs using routinely collected data from registry and administrative hospital datasets to describe real-world receipt of best practice care and identify potential variations across a number of sociodemographic factors.

Material/Methods:

We investigated lung cancer QIs obtained from literature review that were feasible to measure on a state-wide cancer registry linked dataset of all diagnosed public lung cancer patients from 2008 to 2012. 64 QIs were found to be feasible, of which 10 were related to RT for either Non-small cell lung cancer (NSCLC) or Small cell lung cancer (SCLC). Bivariate analysis was also performed on a number of patient characteristics to describe differences in care received.

Results:

Analysis was performed of RT QIs from 12485 patients of which 6048 received RT. These are shown in Table 1.

Table 1 Lung radiotherapy quality indicators